DRI Healthcare Trust (TSE:DHT.UN) Price Target Lowered to C$22.00 at Raymond James

DRI Healthcare Trust (TSE:DHT.UN) had its target price reduced by equities research analysts at Raymond James from C$23.00 to C$22.00 in a research note issued to investors on Wednesday,BayStreet.CA reports. Raymond James’ target price points to a potential upside of 67.56% from the company’s previous close.

Several other research firms also recently commented on DHT.UN. Truist Financial reduced their price target on shares of DRI Healthcare Trust from C$17.00 to C$14.00 in a research report on Thursday, July 25th. Scotiabank increased their target price on shares of DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of C$18.00.

DRI Healthcare Trust Trading Down 1.2 %

DHT.UN traded down C$0.16 during trading on Wednesday, hitting C$13.13. 22,389 shares of the stock were exchanged, compared to its average volume of 43,382. DRI Healthcare Trust has a 1-year low of C$10.39 and a 1-year high of C$17.43. The stock has a fifty day moving average price of C$13.24 and a two-hundred day moving average price of C$13.64.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.